A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)

Inclusion Criteria: * Outpatients * Men and women 22-68 years of age * Subjects currently diagnosed with PTSD according to the DSM-5, using the CAPS-5 (past-month version), with the following criteria met: * Criterion B: at least 1/5 intrusion symptoms; and * Criteria C: at least 1/2 avoidance symptoms; and * Criteria D: at least 2/7 cognition \& mood symptoms; and * Criteria E: at least 2/6 arousal \& reactivity symptoms; and * Criterion F: duration is met; and * Criteria G: distress is met. * Subjects with at least moderate PTSD with a CAPS-5 score ≥ 25 at both Screening and Baseline visits. * Subjects with an HDRS-21 score ≤ 26 at both Screening and Baseline visits. * Subjects with negative or mitigated answers on safety screening questionnaire for transcranial magnetic stimulation. * Negative pregnancy test in childbearing age women. * Subject is capable and willing to provide informed consent. * Subject is able to adhere to the treatment schedule. Exclusion Criteria: * Subject diagnosed according to the SCID I as suffering from any other major Axis I disorder, such as Psychotic Disorder, Bipolar affective disorder, OCD (MDD is not contraindicated when HDRS-21≤26). * Subjects diagnosed according to the SCID II as suffering from Severe Personality Disorder. * Subjects with significant suicidal risk as assessed by the investigator using the Beck Suicide Ideation scale, psychiatric interview or a history of attempted suicide in the past year. * Subject has a history of epilepsy or seizure (EXCEPT those therapeutically induced by ECT). * Subject has a history of significant head trauma with loss of consciousness for longer than 5 minutes. * Subject has a history of cranial surgery. * Subject has metallic particles in the eye or head (exclusive of mouth), implanted cardiac pacemaker or any intra-cardiac lines, implanted neurostimulators, intra-cranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps. * Subject has severe and frequent headaches. * Subject has a history of significant hearing loss. * Subjects with a significant neurological disorder or insult including, but not limited to: * Any condition likely to be associated with increased intracranial pressure * Space occupying brain lesion * History of cerebrovascular accident * Transient ischemic attack within two years * Cerebral aneurysm * MMSE ≤ 24 * Parkinson's disease * Huntington's chorea * Multiple sclerosis * Subject with a history of substance abuse including alcoholism within the past 6 months (except nicotine and caffeine). * Inadequate communication with the patient. * Subject is under custodial care. * Subject is currently participating in another clinical study or enrolled in another clinical study within 30 days prior to this study. * Subject with unstable physical disease such as unstable cardiac disease. * Subject is currently on Benzodiazepine at a dose higher than 3 mg of Lorazepam or equivalent. * Subject has had previous treatment with TMS. * Women who are breast-feeding. * Women of childbearing potential and not using a medically accepted form of contraception when sexually active.